Novo Nordisk’s next-gen medication is called CagriSema. It’s a once-weekly shot that combines a long-acting amylin analogue ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Tirzepatide starts working quickly. You might notice less hunger in a few days or weeks. Average weight loss in 3 weeks is ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study ...

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival's ...

Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of ...